A
Amber C. King
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 24
Citations - 388
Amber C. King is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Venetoclax & Blinatumomab. The author has an hindex of 8, co-authored 20 publications receiving 184 citations.
Papers
More filters
Journal ArticleDOI
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Anthony R. Mato,Lindsey E. Roeker,Ryan Jacobs,Brian T. Hill,Nicole Lamanna,Danielle M. Brander,Mazyar Shadman,Chaitra S. Ujjani,Maryam Sarraf Yazdy,Guilherme Fleury Perini,Javier Pinilla-Ibarz,Jacqueline C. Barrientos,Alan P Skarbnik,Pallawi Torka,Jeffrey J. Pu,John M. Pagel,Satyen H. Gohil,Bita Fakhri,Michael Y. Choi,Catherine C. Coombs,Joanna Rhodes,Paul M. Barr,Craig A. Portell,Helen Parry,Christine A. Garcia,Kate J Whitaker,Allison M. Winter,Andrea Sitlinger,Sirin Khajavian,Ariel F Grajales-Cruz,Krista Isaac,Pratik Shah,Othman S. Akhtar,Rachael Pocock,Kentson Lam,Timothy J Voorhees,Stephen J. Schuster,Thomas D. Rodgers,Christopher P. Fox,Nicolas Martinez-Calle,Talha Munir,Erica B. Bhavsar,Neil Bailey,Jason C. Lee,Hanna Weissbrot,Chadi Nabhan,Julie Goodfriend,Amber C. King,Andrew D. Zelenetz,Colleen Dorsey,Kayla Bigelow,Bruce D. Cheson,John N. Allan,Toby A. Eyre +53 more
TL;DR: It is concluded that BTKi in naïve or previously responsive patients and cellular therapies following venetoclax may be the most effective strategies.
Journal ArticleDOI
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl,Maximilian Stahl,Kamal Menghrajani,Kamal Menghrajani,Andriy Derkach,Alexander Chan,Wenbin Xiao,Jacob L. Glass,Jacob L. Glass,Amber C. King,Anthony F. Daniyan,Anthony F. Daniyan,Christopher Famulare,Christopher Famulare,Bernadette M. Cuello,Troy Z. Horvat,Omar Abdel-Wahab,Ross L. Levine,Aaron D. Viny,Eytan M. Stein,Eytan M. Stein,Sheng F. Cai,Sheng F. Cai,Mikhail Roshal,Martin S. Tallman,Martin S. Tallman,Aaron D. Goldberg,Aaron D. Goldberg +27 more
TL;DR: Azacitidine + venetoclax, decitabine+ venetocaine, and low-dose cytarabine + Venetocax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML).
Journal ArticleDOI
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
TL;DR: This small series suggests blinatumomab’s concurrent with commercially available TKIs as consolidative therapy to spare toxicities of conventional chemotherapy is a safe and effective consolidation strategy for patients with Ph’+ ALL to achieve or maintain CMR.
Journal ArticleDOI
Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies:
TL;DR: Venetoclax has demonstrated promising results in relapsed/refractory lymphoid malignancies, with an acceptable adverse effect profile, and may offer benefit to a myriad other patient populations.
Journal ArticleDOI
Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
Raajit K. Rampal,Srdan Verstovsek,Sean M. Devlin,Amber C. King,Eytan M. Stein,Naveen Pemmaraju,Michael J. Mauro,Tapan M. Kadia,Guillermo Montalban-Bravo,Kelsey Alvarez,Nicole Ard,Tawni Goodman,Bria Taylor,Prithviraj Bose +13 more
TL;DR: Assessment of the effect of combined RUX and THAL in subjects with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis found both disease-related and therapy-related cytopenias were improved and the overall disease response improved.